Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBIT (2022 - 2025)

Historic EBIT for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$43.1 million.

  • Stoke Therapeutics' EBIT fell 4362.23% to -$43.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year increase of 12318.44%. This contributed to the annual value of -$101.4 million for FY2024, which is 1167.61% up from last year.
  • Per Stoke Therapeutics' latest filing, its EBIT stood at -$43.1 million for Q3 2025, which was down 4362.23% from -$27.3 million recorded in Q2 2025.
  • Stoke Therapeutics' EBIT's 5-year high stood at $111.2 million during Q1 2025, with a 5-year trough of -$43.1 million in Q3 2025.
  • For the 4-year period, Stoke Therapeutics' EBIT averaged around -$18.6 million, with its median value being -$27.2 million (2023).
  • Over the last 5 years, Stoke Therapeutics' EBIT had its largest YoY gain of 49207.67% in 2025, and its largest YoY loss of 4362.23% in 2025.
  • Over the past 4 years, Stoke Therapeutics' EBIT (Quarter) stood at -$27.2 million in 2022, then dropped by 8.87% to -$29.6 million in 2023, then skyrocketed by 53.85% to -$13.7 million in 2024, then tumbled by 215.62% to -$43.1 million in 2025.
  • Its EBIT was -$43.1 million in Q3 2025, compared to -$27.3 million in Q2 2025 and $111.2 million in Q1 2025.